How should we think about endocrine resistance in patients with inherited germline mutations such as BRCA, CHEK2, etc.?

Should these patients have a different threshold for utilizing a CDK4/6 inhibitor in the front line metastatic or as part of adjuvant therapy, or SERDs where eligible?

Community PollStarted

Do you have reservations about using SERDs in patients with BRCA and ESR1 mutations?

65 physicians have voted

Join Mednetto vote and see how they answered.

1 Answer

Mednet Member

Medical Oncology · Levine Cancer Institute, Atrium Health

Answered on

In patients with germline mutations such as BRCA1/2, we have learned that the use of CDK4/6 inhibitors may have less of an impact, suggesting some degree of inherent endocrine therapy resistance. In one retrospective analysis of patients with germline mutations in homologous recombination repair (su...

Join for free or sign in to see the full answer